19:57 , Apr 12, 2019 |  BC Extra  |  Company News

Gilead, Novo team up to combine NASH compounds

A day after Gilead presented Phase II data at EASL for its cilofexor plus firsocostat combination to treat non-alcoholic steatohepatitis, the company partnered with Novo Nordisk to test the duo in combination with semaglutide in...
01:56 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Oral insulin innovation

While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in...
02:06 , Feb 9, 2019 |  BioCentury  |  Politics, Policy & Law

Killing Part D rebates

HHS’s proposal to scrap the secret rebates drug manufacturers pay PBMs and health plans in Medicare Part D would help President Donald Trump fulfill promises to reduce drug prices. It would also reduce financial burdens...
22:35 , Feb 7, 2019 |  BC Extra  |  Preclinical News

Novo, MIT develop oral biologic delivery device

A team including Massachusetts Institute of Technology and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) scientists have developed an ingestible pill-sized device that can deliver drugs, including insulin, directly to the gastric mucosa. The device --...
23:15 , Dec 7, 2018 |  BioCentury  |  Emerging Company Profile

ADCendo: entering tumors via MRC2

ADCendo ApS is developing an antibody-drug conjugate against mannose receptor C type 2 (MRC2; UPARAP) that could treat cancers at lower doses and with less toxicity than other ADCs, due to the target’s enriched cancer...
22:59 , Nov 30, 2018 |  BioCentury  |  Emerging Company Profile

Afyx: Mucosal drug delivery

Afyx Therapeutics is developing bioadhesive patches for mucosal drug delivery to address diseases that are inadequately treated by topical agents. Diseases affecting topically accessible mucosal sites, such as the buccal mucosa, are difficult to treat...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) acquired Ziylo Ltd. (Bristol, U.K.), giving the pharma a platform that could help it develop a glucose-responsive insulin. Novo has identified glucose-sensitive insulin as an important innovative area for...
17:56 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms; imaging

TECHNOLOGY: Structural analyses; other An electron microscopy-based method for identifying epitopes that elicit potent neutralizing antibodies could be used to guide the development of vaccines for infectious diseases. The method involves six steps: digesting animal-...
15:38 , Aug 17, 2018 |  BC Extra  |  Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) acquired Ziylo Ltd. (Bristol, U.K.), giving the pharma a platform that could help it develop a glucose-responsive insulin. Novo has identified glucose-sensitive insulin as an important innovative area for...
19:09 , Aug 7, 2018 |  BC Extra  |  Company News

Management tracks: GSK, J&J, Denali

GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) hired Iain Mackay as CFO and executive director. Mackay, who is group finance director at HSBC, will join GSK on Jan. 14, 2019 as CFO designate and take formal accountability as...